10509153

Source:http://linkedlifedata.com/resource/pubmed/id/10509153

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0027651, umls-concept:C0040549, umls-concept:C0205208, umls-concept:C0521451, umls-concept:C0920321
pubmed:issue	8
pubmed:dateCreated	1999-11-16
pubmed:abstractText	MKT077 is a rhodacyanine dye analogue which preferentially accumulates in tumour cell mitochondria. It is cytotoxic to a range of tumours. In this phase I study, MKT077 was administered as a five-day infusion once every three weeks.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/MKT 077, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	0923-7534
pubmed:author	pubmed-author:BraybrookeJ PJP, pubmed-author:CollinsW CWC, pubmed-author:CramerJ AJA, pubmed-author:GanesanT STS, pubmed-author:HarrisA LAL, pubmed-author:LevittN CNC, pubmed-author:LodiRR, pubmed-author:PropperD JDJ, pubmed-author:StylesPP, pubmed-author:TalbotD CDC, pubmed-author:TaylorD JDJ
pubmed:issnType	Print
pubmed:volume	10
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	923-7
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:10509153-Adult, pubmed-meshheading:10509153-Aged, pubmed-meshheading:10509153-Antineoplastic Agents, pubmed-meshheading:10509153-Dose-Response Relationship, Drug, pubmed-meshheading:10509153-Drug Monitoring, pubmed-meshheading:10509153-Drug Resistance, Neoplasm, pubmed-meshheading:10509153-Female, pubmed-meshheading:10509153-Follow-Up Studies, pubmed-meshheading:10509153-Humans, pubmed-meshheading:10509153-Infusions, Intravenous, pubmed-meshheading:10509153-Male, pubmed-meshheading:10509153-Middle Aged, pubmed-meshheading:10509153-Mitochondria, pubmed-meshheading:10509153-Neoplasm Staging, pubmed-meshheading:10509153-Neoplasms, pubmed-meshheading:10509153-Pyridines, pubmed-meshheading:10509153-Severity of Illness Index, pubmed-meshheading:10509153-Thiazoles, pubmed-meshheading:10509153-Treatment Outcome
pubmed:year	1999
pubmed:articleTitle	Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours.
pubmed:affiliation	ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I